Bio-Techne Announces ExoTRU Kidney Transplant Rejection Assay Data Publication
Share this article Share this article MINNEAPOLIS, March 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay. ExoTRU was developed in collaboration with the Azzi laboratory at the Transplantation Research Center at Brigham and Women's Hospital, Harvard Medical School. The ExoTRU test will be the first ever commercially available test capable of d...
Source: prnewswire.com